CD274 and metastatic melanoma: While more patients with NSCLC or rectal cancer have decreased PD-L1 expression [181, 192–194]; Different combination regimens: a retrospective analysis of patients with metastatic melanoma reported a response rate of 64% in patients treated with both stereotactic radiosurgery and anti-PD-1 antibodies, higher than the 44% response rate in patients treated sequentially [195]; Irradiation dose: RT also modulates the immune system and TME in a dose-dependent manner.